What you should know:
1. Despite the overall loss, Medicrea grew its sales from $35.2 million (32.3 million euros) in 2018 to $35.7 million (32.7 million euros) in 2019.
2. The company’s EBITDA also grew from $654,540 (600,000 euros) in 2018 to $3.4 million (3.1 million euros) in 2019.
3. Medicrea said sales were up 16 percent before the COVID-19 pandemic on a year-over-year basis. In the U.S., sales rose 10 percent year over year.
4. The COVID-19 pandemic has affected Medicrea heavily. The company suffered a 5 percent drop in first-quarter year-over-year sales.
5. To mitigate losses from the pandemic, the company capitalized on a European tax credit, collected 40 percent of the trade receivables on its balance sheet, placed its U.S.-based employees on furlough, and sought financial relief from its main creditor.
6. Medicrea also applied for a $1 million loan through the Paycheck Protection Program.
Note: All monetary conversions were current as of April 13.
More articles on surgery centers:
5 ways ASCs could be affected long after the pandemic
Outcomes for 147 spinal disc replacements in an ASC: 5 key notes
Texas cardiovascular company developing triangular ASC — 3 details
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.